Omnicell, Inc. (NASDAQ:OMCL) CEO Randall A. Lipps sold 3,718 shares of the business’s stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $75.15, for a total transaction of $279,407.70. Following the transaction, the chief executive officer now owns 152,116 shares in the company, valued at approximately $11,431,517.40. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Shares of OMCL stock opened at $71.33 on Friday. The firm has a 50-day moving average of $67.15 and a 200-day moving average of $72.74. The company has a market cap of $3.10 billion, a P/E ratio of 40.14, a P/E/G ratio of 2.88 and a beta of 1.03. Omnicell, Inc. has a one year low of $54.24 and a one year high of $94.85.

Omnicell (NASDAQ:OMCL) last announced its earnings results on Tuesday, July 28th. The company reported $0.37 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.23 by $0.14. The company had revenue of $199.62 million during the quarter, compared to the consensus estimate of $182.16 million. Omnicell had a net margin of 5.42% and a return on equity of 9.21%. The firm’s revenue for the quarter was down 8.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.67 earnings per share. On average, equities research analysts predict that Omnicell, Inc. will post 1.68 earnings per share for the current year.

A number of research analysts recently issued reports on the stock. Cantor Fitzgerald boosted their target price on shares of Omnicell from $85.00 to $90.00 and gave the company an “overweight” rating in a research report on Wednesday. Benchmark lowered their price objective on shares of Omnicell from $96.00 to $82.00 and set a “buy” rating on the stock in a report on Friday, May 8th. BidaskClub downgraded shares of Omnicell from a “hold” rating to a “sell” rating in a report on Wednesday, July 8th. Stephens began coverage on shares of Omnicell in a report on Monday, July 6th. They set an “overweight” rating and a $90.00 price objective on the stock. Finally, ValuEngine downgraded shares of Omnicell from a “buy” rating to a “hold” rating in a report on Friday, April 17th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company’s stock. Omnicell currently has a consensus rating of “Hold” and a consensus price target of $85.50.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Conestoga Capital Advisors LLC grew its position in Omnicell by 5.6% during the first quarter. Conestoga Capital Advisors LLC now owns 1,665,760 shares of the company’s stock valued at $109,241,000 after buying an additional 88,016 shares during the period. State Street Corp grew its position in Omnicell by 8.1% during the first quarter. State Street Corp now owns 1,303,978 shares of the company’s stock valued at $85,515,000 after buying an additional 97,154 shares during the period. Bank of New York Mellon Corp grew its position in Omnicell by 62.3% during the first quarter. Bank of New York Mellon Corp now owns 877,992 shares of the company’s stock valued at $57,578,000 after buying an additional 337,035 shares during the period. Waddell & Reed Financial Inc. grew its position in Omnicell by 16.6% during the first quarter. Waddell & Reed Financial Inc. now owns 637,803 shares of the company’s stock valued at $41,827,000 after buying an additional 90,934 shares during the period. Finally, Geode Capital Management LLC grew its position in Omnicell by 6.6% during the first quarter. Geode Capital Management LLC now owns 611,079 shares of the company’s stock valued at $40,074,000 after buying an additional 37,756 shares during the period. Institutional investors own 95.79% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.

Recommended Story: Quiet Period Expirations

Insider Buying and Selling by Quarter for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.